Skip to main content

Table 3 Toxicity according to National Cancer Institute common toxicity criteria version 3

From: Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial

Adverse event All grades   Grade 3/4  
(safety population n = 78)
  pts (n) % pts (n) %
Leucopenia 2 2 0 0
Anemia 4 5 1 1
Thrombocytopenia 4 5 1 1
Infection 29 37 6 7
Fatigue/Asthenia 20 25 1 1
Diarrhea 26 33 5 6
Mucositis 14 18 1 1
Nausea 22 28 4 5
Vomiting 9 12 1 1
Anorexia 8 10 1 1
Hand-foot-syndrome 44 57 16 21
Gastrointestinal perforation 2 2 2 2
Hemorrhage 10 13 1 1
Hypertension 17 22 3 4
Thromboembolic events 12 15 8 10
  1. Abbreviation: pts (n) number of patients.